Prospective Randomized Eye-to-Eye Comparison of 150 kHz Femtosecond Laser to 60 kHz Femtosecond Laser for LASIK:  1-Year Results

Monday, April 28, 2014: 3:01 PM
Room 154 (Boston Convention and Exhibition Center)
Edward E. Manche, MD, Stanford Univ School of Medicine, Palo Alto, CA, USA
Charles Q. Yu, MD, Byers Eye Institute at Stanford, Palo Alto, CA, USA

Narrative Responses:

Purpose
To prospectively compare LASIK outcomes between two femtosecond laser systems in the treatment of myopia.  Outcome measures include, patient self-reported preference, high contrast snellen acuity, low contrast snellen acuity (25% and 5%), safety, efficacy, predictability, flap thickness and higher order aberration analysis.

Methods
One-hundred and twenty-two eyes of 61 consecutive patients were treated with wavefront-guided LASIK.  One eye had a flap created with the AMO Intralase IFS 150 kHz laser system and the fellow eye had a flap created with the AMO Intralase FS 60 kHz laser system.  Eyes were randomized according to ocular dominance.  The mean pre-operative spherical equivalent refraction was -4.35 +/- 2.31 and -4.32 +/-2.31 in the FS60 group IFS group respectively. There were no statistically significant differences in pre-operative higher order aberrations between the two groups.

Results
At post op month twelve, 92% of eyes in both groups were within 0.50 diopters of the intended correction. At the 12-month post-op visit, the mean spherical equivalent refraction was -0.07 +/- 0.20 diopters in the FS60 group and -0.14 +/- 0.25 diopters in the IFS group. At post-operative day one, week one and month one, a statistically significant greater percentage of eyes in the IFS 150 treated group had an uncorrected visual acuity of 20/20, 20/16 and 20/12.5 compared to the FS60 group.

Conclusion
Wavefront-guided LASIK using the IFS150 yielded better UCVA results compared to the FS60 in the early postoperative period.  There were no significant differences in safety, predictability, or changes in HOA between the two groups.  There were no statistically significant differences in clinical outcomes between the two platforms after one month.